Manolete Partners (MANO) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
13 Jun, 2025Executive summary
UK's leading insolvency litigation financing company with a 67% market share in the third-party funder segment.
Achieved record case completions and cash generation in H1 FY25, with 137 completions and gross cash collected up 63% to £14.3m.
Realised revenues hit a record £15.0m, up 60% year-over-year, driven by strong operational leverage.
New case investment opportunities reached a record 437, up 27% from H1 FY24, indicating a strong pipeline.
Recognized as a five-time winner of the TRI award and consistently top-ranked by Chambers for litigation support.
Financial highlights
Realised revenue rose 60% to £15.0m in H1 FY25; total revenue up 28% to £14.4m.
Gross cash generation from completed cases increased 63% to £14.3m.
Gross profit fell 12% to £4.4m, with realised gross margin stable at 33% and operating margin at 5% (down from 14%).
EBIT dropped 58% to £0.7m; PBT swung to a loss of £0.2m (H1 FY24: profit £0.9m) due to higher overheads and negative unrealised revenue.
Net debt at £11.9m, with £0.6m cash and £12.5m drawn on HSBC RCF.
Outlook and guidance
Case completions and cash generation expected to remain strong, with focus on increasing average realised revenue per case.
Board aims to restore average realised revenue per completed case to pre-pandemic levels while maintaining high case volumes.
Loan refinancing discussions with HSBC to begin in January 2025; exploring additional funding sources.
No interim dividend is proposed for H1 FY25.
The company is well positioned to benefit from high insolvency levels and challenging economic conditions.
Latest events from Manolete Partners
- Revenue down 12%, but record case activity and strong H2 outlook support growth.MANO
H1 202619 Nov 2025 - Record revenues, strong cash flow, and increased new case investments drive profit growth.MANO
H2 20259 Nov 2025 - FY24 delivered strong revenue growth, record case completions, and a positive outlook.MANO
H2 202413 Jun 2025